NanoViricides, Inc. (NYSE American: NNVC) announced that its clinical-stage antiviral drug NV-387 has been granted Orphan Drug Designation by the U.S. FDA for the treatment of measles. This designation provides potential incentives including tax credits, fee exemptions, and market exclusivity, which could accelerate the drug's development and regulatory pathway. The company highlighted that NV-387 is a broad-spectrum antiviral candidate that has demonstrated in vivo activity against measles and is being developed to address rising global outbreaks.
Orphan Drug Designation is granted by the FDA to drugs intended to treat rare diseases affecting fewer than 200,000 people in the United States. While measles is not rare globally, the designation reflects the need for treatments in specific populations and the potential for NV-387 to fill an unmet medical need. The incentives include tax credits for clinical trial costs, exemption from certain FDA fees, and seven years of market exclusivity upon approval, which can significantly reduce development costs and enhance commercial prospects.
NV-387 is a broad-spectrum antiviral drug that the company plans to develop for respiratory viral infections such as RSV, COVID-19, Long COVID, and influenza. It has also shown effectiveness in animal models for monkeypox (MPox), smallpox, and measles. The drug successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events, and the company is currently focused on advancing NV-387 into Phase II human clinical trials.
The announcement comes amid increasing global measles outbreaks, with the World Health Organization reporting a rise in cases due to disruptions in vaccination programs. NanoViricides' approach using nanomaterials for antiviral therapy could offer a novel treatment option for measles, which currently lacks specific antiviral therapies. The company's lead drug candidate, NV-387, is a unique broad-spectrum antiviral that targets multiple viruses, potentially addressing both current and future viral threats.
For more information, visit the company's newsroom at https://ibn.fm/NNVC. The full press release is available at https://ibn.fm/uIWWv.
NanoViricides is a clinical-stage company creating special purpose nanomaterials for antiviral therapy. The company's other advanced drug candidate is NV-HHV-1 for the treatment of herpesvirus infections. The company cannot project an exact date for filing an IND for any of its drugs due to dependence on external collaborators and consultants.
